Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy of Cholesterol-lowering Probiotic Lactobacillus Plantarum LPLDL® in Hypercholesterolemic Adults. (ProLoChol)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03540108
Recruitment Status : Not yet recruiting
First Posted : May 30, 2018
Last Update Posted : April 10, 2019
Sponsor:
Information provided by (Responsible Party):
DR ADELE COSTABILE, University of Roehampton

Brief Summary:
Coronary heart disease (CHD) is one of the major causes of death and disability in industrialised countries. Results from several epidemiological and clinical studies indicate a positive correlation between elevated total serum cholesterol levels, mainly reflecting the LDL-cholesterol fraction, and risk of CHD. It is thought that a reduction in total plasma cholesterol levels in populations suffering from primary hypercholesterolemia (elevated cholesterol) can lower the incidence of coronary thrombosis. Currently, therefore there is extensive interest in the management of serum cholesterol and other blood lipids. Diet is viewed as a major influencing factor that can reduce levels. This is largely driven by the expense of drug therapy, the large numbers of individuals affected and unwanted side effects of such treatments. Dietary strategies for prevention of CHD implicate adherence to a low-fat/low-saturated fat diet. Although such diets may present an effective approach, they are difficult to maintain on a long-term basis and efficacy diminishes over time. As such, new approaches towards identification of other dietary means of reducing blood cholesterol levels have been evaluated. These include, among others, the use of probiotics. Probiotics are 'live microbial feed supplements that offer a benefit to health'. They are marketed as health or functional foods whereby they are ingested for their purported positive advantages in the digestive tract and/or systemic areas like the liver, vagina or bloodstream. The main goal of the study is to test the efficacy of the probiotic in degrading cholesterol as well as produce metabolites that interfere with its synthesis in the liver in adults with high cholesterol (>6mmol). The effect may also be partially ascribed to an enzymatic deconjugation of bile acids.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Dietary Supplement: Lactobacillus plantarum ECGC 13110402 Dietary Supplement: Placebo Comparator: Maltodextrin Not Applicable

Detailed Description:
The aim of this human volunteer study is to establish the extent of extent of the cholesterol lowering potential of Lactobacillus plantarum ECGC 13110402 in 50 hypercholesterolaemic adults (35-70 years old).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-centre, prospective, randomised, placebo-controlled, parallel-group design to determine the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 (LPLDL® in hypercholesterolaemic adults (>6mmol).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum ECGC 13110402 (LPLDL®) in Hypercholesterolemic Adults
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : May 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental: L. plantarum ECGC 13110402 (LPLDL®)
Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
Dietary Supplement: Lactobacillus plantarum ECGC 13110402
The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).

Placebo Comparator: Placebo Comparator: Maltodextrin
Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
Dietary Supplement: Placebo Comparator: Maltodextrin
Please see intervention description above.




Primary Outcome Measures :
  1. Cholesterol-lowering efficacy [ Time Frame: from baseline to 6 and 12 weeks of the intervention ]
    To test, in humans, whether the LPLDL® intervention lowers total cholesterol by a log change of min. 0.45 ± 0.4.

  2. Effect on the gut microbiota [ Time Frame: from baseline to 6 and 12 weeks of the intervention ]
    To determine the effect of LPLDL® on the faecal microbiota composition and microbial activity of the volunteers using DNA profiling from faeces (16s rRNA sequencing using Illumina MiSeq Platform and QIIME data analysis software).

  3. Effect on vitamin D absorption and ABOB [ Time Frame: from baseline to 6 and 12 weeks of the intervention ]
    To investigate the effect of LPLDL® on vitamin D absorption in the study population by measuring circulating vitamin D in blood using clinical chemistry and monitoring vitamin D intake from food diary.

  4. Effect on bile acid metabolism [ Time Frame: from baseline to 6 and 12 weeks of the intervention ]
    To assess any changes in bile acid metabolites and TMAO during the study trial using high performance liquid chromatography tandem mass spectrometry to analyse the urine samples.


Secondary Outcome Measures :
  1. Digestive symptoms [ Time Frame: from baseline to 6 and 12 weeks of the intervention ]
    Bristol diary form Bristol diary form.

  2. Dietary assessment [ Time Frame: from baseline to 6 and 12 weeks of the intervention ]
    To conduct an assessment of dietary intake in the study population using a validated four-day food diary and dietplan 7 dietary analysis software (Forestfield Ltd.)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • males and females from 35 to 70 years of age
  • BMI 18.5 to 29.9 kg/m2
  • total cholesterol (TC) >6mmol/L.

Exclusion Criteria:

  • suffering from chronic gastrointestinal complaints (including chronic constipation, diarrhoea or Irritable Bowel Syndrome)
  • diabetes or anaemia
  • requirement to take long-term medications active on the gastrointestinal tract, treatment of cardio-vascular disease, or any other long-term medication
  • high blood cholesterol or use of cholesterol lowering drugs/ functional foods
  • history of drug or alcohol misuse or alcohol consumption exceeding 14 and 21 units/week for females and males respectively
  • those suffering with any allergies to medication or food
  • on weight-reducing diets.
  • Females planning pregnancy within six months from the start of the study, lactating, or have given birth within the preceding six months
  • use of antibiotics within six months preceding the study, participation in any probiotic, prebiotic or laxative study or intake of an experimental drug four weeks prior to the study start.
  • Individuals exercising > 16 744 kJ per week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03540108


Contacts
Layout table for location contacts
Contact: Adele Dr Costabile, PhD +44 (0) 20 8392 3571 adele.costabile@roehampton.ac.uk

Sponsors and Collaborators
University of Roehampton

Layout table for additonal information
Responsible Party: DR ADELE COSTABILE, Senior Lecturer in Nutrition, University of Roehampton
ClinicalTrials.gov Identifier: NCT03540108     History of Changes
Other Study ID Numbers: LSC 18/ 241
First Posted: May 30, 2018    Key Record Dates
Last Update Posted: April 10, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by DR ADELE COSTABILE, University of Roehampton:
hypercholesterolemia
bile acid synthesis
cholesterol
bile salt hydrolysis
vitamin D
probiotic L plantarum LPLDL®
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases